Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bioheart, a biotechnology company, has received a notice of allowance from the US Patent and Trademark Office for nine new patent claims covering the use of electrical stimulation to enhance stem cell regeneration of damaged heart muscle.
Subscribe to our email newsletter
The invention and its claims are said to be pioneering in that they harness the natural electro-chemical instructional program that teaches stem cells to become heart muscle and then apply this process to damaged heart muscle in patients suffering from heart failure.
The claims of the patent also cover pre-conditioning stem cells towards a cardiac phenotype by electrically stimulating them during culture before implantation into damaged heart muscle.
The inventors, Howard Leonhardt, chairman, CEO and chief technology officer of Bioheart, and Juan Chachques, associate professor cardiac surgery, Pompidou Hospital, Paris, France have previously partnered to receive other related patents for complementary devices and methods.
David Holmes, chairman of cardiology at Mayo Clinic, Rochester, Minnesota, said: “This truly has the potential to be a landmark invention in the field of heart failure treatment.”